• 1
    Kraan MC, Haringman JJ, Weedon H, Barg EC, Smith MD, Ahern MJ, et al. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004; 63: 4838.
  • 2
    Walsh D, Pearson C. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res Ther 2001; 3: 14753.
  • 3
    Kennedy A, Ng CT, Biniecka M, Saber T, Taylor C, O'Sullivan J, et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 2010; 62: 71121.
  • 4
    Ng CT, Biniecka M, Kennedy A, McCormick J, FitzGerald O, Bresnihan B, et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 2010; 69: 138995.
  • 5
    Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51: 91925.
  • 6
    Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell–derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002; 46: 258797.
  • 7
    Ahn J, Koh E, Cha H, Lee Y, Kim J, Bae E, et al. Role of hypoxia-inducible factor-1α in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 2008; 47: 8349.
  • 8
    Akhavani M, Madden L, Buysschaert I, Sivakumar B, Kang N, Paleolog E. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther 2009; 11: R64.
  • 9
    Maurice M, Nakamura H, van der Voort E, van Vliet A, Staal F, Tak P, et al. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J Immunol 1997; 158: 145865.
  • 10
    Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999; 80: 1697707.
  • 11
    Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum 1970; 13: 76976.
  • 12
    Treuhaft PS, McCarty DJ. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum 1971; 14: 47584.
  • 13
    Sivakumar B, Akhavani MA, Winlove CP, Taylor PC, Paleolog EM, Kang N. Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg Am 2008; 33: 4958.
  • 14
    Oliver KM, Garvey JF, Ng CT, Veale DJ, Fearon U, Cummins EP, et al. Hypoxia activates NF-κB dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal 2009; 11: 205764.
  • 15
    Biniecka M, Kennedy A, Fearon U, Ng CT, Veale DJ, O'Sullivan JN. Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann Rheum Dis 2010; 69: 11728.
  • 16
    Stevens CR, Williams RB, Farrell AJ, Blake DR. Hypoxia and inflammatory synovitis: observations and speculation. Ann Rheum Dis 1991; 50: 12432.
  • 17
    Bodamyali T, Stevens C, Billingham M, Ohta S, Blake D. Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis 1998; 57: 70310.
  • 18
    Jeon C, Ahn J, Chai J, Kim H, Bae E, Park S, et al. Hypoxia appears at pre-arthritic stage and shows co-localization with early synovial inflammation in collagen induced arthritis. Clin Exp Rheumatol 2008; 26: 6468.
  • 19
    Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 20
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 3545.
  • 21
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 22
    Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48: 215562.
  • 23
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 24
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 266573.
  • 25
    Van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65: 15517.
  • 26
    Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones P, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003; 30: 2608.
  • 27
    Rhodes LA, Grainger AJ, Keenan AM, Thomas C, Emery P, Conaghan PG. The validation of simple scoring methods for evaluating compartment-specific synovitis detected by MRI in knee osteoarthritis. Rheumatology (Oxford) 2005; 44: 156973.
  • 28
    Naughton DP, Haywood R, Blake DR, Edmonds S, Hawkes GE, Grootveld M. A comparative evaluation of the metabolic profiles of normal and inflammatory knee-joint synovial fluids by high resolution proton NMR spectroscopy. FEBS Lett 1993; 332: 2215.
  • 29
    Choy EH, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, et al. Percentage of anti-CD4 monoclonal antibody–coated lymphocytes in the rheumatoid joint is associated with clinical improvement: implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996; 39: 526.
  • 30
    Dombrecht E, Aerts N, Schuerwegh A, Hagendorens M, Ebo D, van Offel J, et al. Influence of anti-tumor necrosis factor therapy (adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 317.
  • 31
    Kane D, Gogarty M, O'Leary J, Silva I, Bermingham N, Bresnihan B, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004; 50: 328695.
  • 32
    Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford) 2008; 47: 14618.
  • 33
    Veale DJ, Reece RJ, Parsons W, Radjenovic A, O'Connor PJ, Orgles CS, et al. Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis 1999; 58: 3429.
  • 34
    Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 8348.
  • 35
    Bresnihan B, Pontifex E, Thurlings R, Vinkenoog M, El-Gabalawy H, Fearon U, et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol 2009; 36: 18002.
  • 36
    Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor-α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 228.
  • 37
    Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti–tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 107781.
  • 38
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 39
    Izquierdo E, Canete JD, Celis R, Santiago B, Usategui A, Sanmarti R, et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One 2009; 4: e8131.
  • 40
    Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12: 44350.
  • 41
    Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an α-v-β-3 antagonist. J Clin Invest 1999; 103: 4754.
  • 42
    Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 22031.
  • 43
    Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 2329.
  • 44
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 5862.
  • 45
    Foley-Nolan D, Stack JP, Ryan M, Redmond U, Barry C, Ennis J, et al. Magnetic resonance imaging in the assessment of rheumatoid arthritis: a comparison with plain film radiographs. Rheumatology (Oxford) 1991; 30: 1016.
  • 46
    Gramas DA, Antounian FS, Peterfy CG, Genant HK, Lane NE. Assessment of needle arthroscopy, standard arthroscopy, physical examination, and magnetic resonance imaging in knee pain: a pilot study. J Clin Rheumatol 1995; 1: 2634.
  • 47
    Konig H, Sieper J, Wolf KJ. Rheumatoid arthritis: evaluation of hypervascular and fibrous pannus with dynamic MR imaging enhanced with Gd-DTPA. Radiology 1990; 176: 4737.
  • 48
    Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010; 69: 5106.
  • 49
    Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging. Ann Rheum Dis 2010; 69: 2069.
  • 50
    Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug– induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 37613.